CAM
LGND icon

ClariVest Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

ClariVest Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.41M Hold
16,768
– – 0.14% 194
2024
Q2 		$1.41M Buy
16,768
+6
+0% +$477 0.14% 194
2024
Q1 		$1.23M Sell
16,762
-83
-0.5% -$6.12K 0.13% 230
2023
Q4 		$1.2M Sell
16,845
-1,010
-6% -$59.6K 0.07% 216
2023
Q3 		$1.07M Buy
17,855
+5
+0% +$329 0.06% 227
2023
Q2 		$1.29M Sell
17,850
-2,690
-13% -$202K 0.06% 194
2023
Q1 		$1.51M Buy
20,540
+7
+0% +$498 0.07% 212
2022
Q4 		$1.37M Sell
20,533
-12,486
-38% -$812K 0.07% 229
2022
Q3 		$1.77M Buy
33,019
+32,977
+78,517% +$1.94M 0.09% 175
2022
Q2 		$2K Buy
+42
New +$2.38K ﹤0.01% 556
2019
Q4 		– Sell
-32,365
Closed -$2.01M – 683
2019
Q3 		$2.01M Sell
32,365
-15,549
-32% -$976K 0.05% 258
2019
Q2 		$3.41M Sell
47,914
-320
-0.7% -$23.6K 0.08% 196
2019
Q1 		$3.78M Sell
48,234
-2,418
-5% -$183K 0.08% 217
2018
Q4 		$4.29M Buy
50,652
+13,381
+36% +$1.43M 0.09% 192
2018
Q3 		$6.38M Buy
37,271
+1,744
+5% +$263K 0.11% 135
2018
Q2 		$4.59M Buy
35,527
+21,637
+156% +$2.41M 0.08% 206
2018
Q1 		$1.43M Buy
13,890
+160
+1% +$15.8K 0.02% 378
2017
Q4 		$1.17M Buy
+13,730
New +$1.19M 0.02% 407
2017
Q1 		– Sell
-29,545
Closed -$1.87M – 719
2016
Q4 		$1.87M Sell
29,545
-29
-0.1% -$1.83K 0.05% 274
2016
Q3 		$1.88M Hold
29,574
– – 0.05% 227
2016
Q2 		$2.2M Buy
29,574
+4,008
+16% +$297K 0.07% 189
2016
Q1 		$1.71M Buy
25,566
+986
+4% +$59.9K 0.05% 219
2015
Q4 		$1.66M Sell
24,580
-513
-2% -$31.7K 0.05% 213
2015
Q3 		$1.34M Sell
25,093
-642
-2% -$39K 0.04% 232
2015
Q2 		$1.62M Buy
+25,735
New +$1.4M 0.05% 230
2014
Q1 		– Sell
-194
Closed -$6K – 627
2013
Q4 		$6K Sell
194
-133
-41% -$4.33K ﹤0.01% 522
2013
Q3 		$9K Hold
327
– – ﹤0.01% 474
2013
Q2 		$8K Buy
+327
New +$5.88K ﹤0.01% 447

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

ClariVest Asset Management's LGND Position: Q3 2024 in Review

ClariVest Asset Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2024 at 16,768 shares worth $1.41M. The position accounts for 0.14% of the portfolio, ranked #194.

ClariVest Asset Management first reported a position in LGND in Q2 2013 and has held it in 28 quarters since. The position peaked at $6.38M in Q3 2018. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • ClariVest Asset Management held 16,768 shares of Ligand Pharmaceuticals worth $1.41M as of Q3 2024.
  • ClariVest Asset Management left its Ligand Pharmaceuticals share count unchanged in Q3 2024.
  • Ligand Pharmaceuticals made up 0.14% of ClariVest Asset Management's portfolio in Q3 2024, its #194 holding.
  • ClariVest Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
  • ClariVest Asset Management's Ligand Pharmaceuticals position peaked at $6.38M in Q3 2018.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.